Viking Therapeutics at $39.96 after 5 percent decline – analyst target remains at $93.60

Viking Therapeutics Inc. (VKTX) recorded a price decline of 5.15 percent on July 8, 2026 and closed at $39.96. The intraday high was $42.00, the low was $38.84. Trading volume was 69,583 shares.

Technical indicators show overbought market conditions

The Relative Strength Index (RSI) reached a value of 74.67 on July 7, 2026 – a level typically considered overbought. The RSI measures the momentum of price movements on a scale of 0 to 100; values above 70 point to a possible overheating. As early as June 29, the RSI was at 75.36, while in mid-June it was still in the neutral range around 50.

Recent RSI values at a glance:

• July 7: 74.67
• July 6: 68.02
• June 30: 72.56
• June 29: 75.36
• June 24: 75.03

Analysts see significant upside potential

The average price target of analysts is $93.60 (as of July 8, 2026), which represents upside potential of approximately 134 percent relative to the current price. Of 24 analysts surveyed, 22 recommend the stock as a buy, with one analyst recommending a hold. There are no sell recommendations.

The price target range spans from $83 (lowest target) to $101 (highest target), with a median of $95. The range shows that despite varying valuations, analysts are uniformly confident in substantial appreciation potential.

Clinical pipeline focused on metabolic diseases

Viking Therapeutics develops therapies for metabolic and endocrine disorders. The lead development program VK2809 is an orally available, tissue and receptor-selective agonist of thyroid hormone receptor beta (TRβ). The drug is currently in Phase IIb studies for the treatment of non-alcoholic steatohepatitis (NASH) – an advanced form of fatty liver disease – as well as non-alcoholic fatty liver disease (NAFLD).

Additional candidates in the development pipeline:

• VK5211: An oral, non-steroidal selective androgen receptor modulator in Phase II for patients following non-elective hip fracture surgery
• VK0612: Orally available drug for type 2 diabetes, ahead of Phase IIb studies
• VK0214: Another oral candidate in development

Market environment pressures biotechnology sector

The price decline on July 8 coincided with a weaker overall market. According to current market reports, a decline in chip stocks pulled major U.S. indices down, while defensive sectors performed better. Biotechnology stocks often react sensitively to broader market movements, as they are frequently classified as risky growth stocks.

Viking Therapeutics, as a clinical-stage biotechnology company – meaning without approved products and revenues – is particularly dependent on investor sentiment and capital market conditions. Financing ongoing studies and future development phases requires regular access to capital.

Valuation and risk profile

The positive assessment by analysts is based on the potential of the development pipeline, particularly VK2809 for liver diseases. The market for NASH therapies is considered promising since currently only limited treatment options exist and disease prevalence is rising.

The risk profile remains typical for a clinical-stage biotechnology company: success depends on positive study results, regulatory approvals, and ultimately market acceptance. Setbacks in clinical trials can lead to significant stock losses. The currently high RSI values suggest that investors have reacted optimistically to the company in recent weeks – the stock has posted a significant gain since mid-June.